Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Losartan in Cystic Fibrosis
NCT03435939Phase 1Completed
- Sponsor
- University of Kansas Medical Center
- Start
- Feb 2022
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of losartan in cystic fibrosis (CF), sponsored by University of Kansas Medical Center. Primary endpoint: Improvement of mucociliary clearance and cough clearance at 12 weeks. Started Feb 2022; status: completed.
02
Drugs
losartan
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT03435939.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03435939.